Boryung’s Two-Track R&D Strategy: Innovative Drugs And Cash Cows
Initial Oncology Focus
Executive Summary
Boryung’s chief technology officer outlines R&D strategy to move forward as a Korea-based global pharma firm and how domestic pharmas are juggling new drug development and generating cash cows.
You may also be interested in...
China Rush Over? Korean Firms Step Up To Seize Opportunities
Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.
Time To Shop? SK Sees ‘Biggest Opportunity’ For Biotech Investment
At a recent forum in Seoul, SK Group unveiled its biotech investment strategy and noted the next few years could present multiple major opportunities for Korean biotechs.
Bracing For The Cold: Time For Korean Bioventures To Cut Down
A recent forum in South Korea heard from a venture capital executive about the changing IPO and financing environment and how bioventures might be able to cope with these changes.